Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. In a recent update, Eli Lilly and Company announced the ...

Colorectal cancer (CRC) is a significant global health concern, originating from precancerous polyps in the colon or rectum and progressing through ...

Immuneering (NASDAQ:IMRX) said it has entered into a clinical supply agreement with Eli Lilly (NYSE:LLY) for its cancer drug ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

The firm is advancing ELI-002 after seeing a positive Phase I readout this month and is expecting initial results from a randomized Phase II study this year.

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Dubbed the ‘guardian of the genome’, the p53 protein responds to DNA damage by stalling cell division, initiating DNA repair ...

RAS is the most mutated oncogene in cancer (about 30% rate), where mutations in KRAS are the most prevalent. The approval of covalent KRAS G12C inhibitors has shown allosteric inhibition of KRAS to be ...

Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay ...

Researchers recently discovered that an experimental cancer vaccine offers "a promising approach" to preventing cancers from ...